Cetuximab: Its unique place in head and neck cancer treatment

Biologics: Targets and Therapy

Volumn 7, Issue 1, 2013, Pages 77-90

  Specenier, Pol ^a   Vermorken, Jan B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Cetuximab; Chemoradiation; Locoregionally advanced; Recurrent metastatic; SCCHN

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HYDROXYUREA; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLACEBO; TRANSFORMING GROWTH FACTOR ALPHA;

ACNE; ACUTE TOXICITY; ANEMIA; ANOREXIA; APOPTOSIS; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CHEILITIS; CHEMORADIOTHERAPY; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPHAGIA; DYSPNEA; ENTERITIS; EVENT FREE SURVIVAL; FAILURE FREE SURVIVAL; FATIGUE; FEBRILE NEUTROPENIA; GENE OVEREXPRESSION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEALTH CARE COST; HEART DISEASE; HUMAN; HYPOMAGNESEMIA; HYPOPHARYNX CARCINOMA; HYPOPHARYNX SQUAMOUS CELL CARCINOMA; INFECTION; INTESTINE PERFORATION; KIDNEY DISEASE; LARYNX SQUAMOUS CELL CARCINOMA; LEUKOPENIA; LOADING DRUG DOSE; LUNG DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIATION DERMATITIS; RADIATION DOSE FRACTIONATION; RECOMMENDED DRUG DOSE; RECURRENCE FREE SURVIVAL; SEPSIS; SIDE EFFECT; SINGLE DRUG DOSE; STEREOTACTIC BODY RADIATION THERAPY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; UPPER GASTROINTESTINAL BLEEDING; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 84876232194     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S43628     Document Type: Article

References (109)

1. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med. 2001;345(26):1890-1900.
2. The Globocan Project [website on the Internet]. Geneva: World Health Organization; 2010. Available from: http://globocan.iarc.fr/. Accessed January 27, 2013.
3. Head and Neck Cancers [website on the Internet]. Bethesda: National Institutes of Health; 2013. Available from: http://www.cancer.gov/cancertopics/factsheet/sites-types/head-and-neck. Accessed January 27, 2013.
4. Marur S, D'Souza G, Westra WH, Forastiere AA. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol. 2010;11(8):781-789.
5. Näsman A, Attner P, Hammarstedt L, et al. Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer. 2009;125(2):362-366.
6. Attner P, Näsman A, Du J, et al. Survival in patients with human papillomavirus positive tonsillar cancer in relation to treatment. Int J Cancer. 2012;131(5):1124-1130.
7. Attner P, Du J, Näsman A, et al. Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer. 2011;128(12):2892-2897.
8. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008;359(11):1143-1154.
9. Ang KK. Multidisciplinary management of locally advanced SCCHN: optimizing treatment outcomes. Oncologist. 2008;13(8):899-910.
10. Grégoire V, Lefebvre JL, Licitra L, Felip E; EHNS-ESMO-ESTRO Guidelines Working Group. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v184-v186.
11. Specenier PM, Vermorken JB. Recurrent head and neck cancer: current treatment and future prospects. Expert Rev Anticancer Ther. 2008;8(3):375-391.
12. Grandis JR. Established and emerging concepts in epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2007;69(Suppl 2):S22-S24.
13. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53(15):3579-3584.
14. Dassonville O, Formento JL, Francoual M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 1993;11(10):1873-1878.
15. Ang KK, Andratschke NH, Milas L. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy. Int J Radiat Oncol Biol Phys. 2004;58(3):959-965.
16. Specenier P, Vermorken JB. Biologic therapy in head and neck cancer: a road with hurdles. ISRN Oncol. 2012;2012:163752.
17. Specenier PM, Vermorken JB. Targeted therapies in head and neck cancer. Target Oncol. 2007;2(2):73-88.
18. Specenier P, Vermorken JB. Cetuximab in the treatment of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther. 2011; 11(4):511-524.
19. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999;59(8):1935-1940.
20. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm. 1999;14(6):451-463.
21. Zhang N, Erjala K, Kulmala J, et al. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro. Radiother Oncol. 2009;92(3):388-392.
22. Fan Z, Baselga J, Masui H, Mendelsohn J. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res. 1993;53(19):4637-4642.
23. Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol. 2008;48(3):267-278.
24. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 2000;18(4):904-914.
25. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 2001;7(5):1204-1213.
26. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 2001;19(13):3234-3243.
27. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006; 354(6):567-578.
28. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-28.
29. European Medicines Agency. Erbitux: EPAR-Product Information. London: European Medicines Agency; 2009. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdf. Accessed January 27, 2013.
30. US Food and Drug Administration. Silver Spring: US Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda_docs//label/2004/125084lbl.pdf. Accessed January 27, 2013.
31. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4-14.
32. Koutcher L, Sherman E, Fury M, et al. Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):915-922.
33. Walsh L, Gillham C, Dunne M, et al. Toxicity of cetuximab versus cisplatin concurrent with radiotherapy in locally advanced head and neck squamous cell cancer (LAHNSCC). Radiother Oncol. 2011;98(1):38-41.
34. Chew A, Hay J, Laskin JJ, Wu J, Ho C. Toxicity in combined modality treatment of HNSCC: Cisplatin versus cetuximab. J Clin Oncol. 2011;29Suppl:Abstr 5526.
35. Shapiro LQ, Sherman EJ, Koutcher L, et al. Efficacy of concurrent cetuximab (C225) versus 5-fluorouracil/carboplatin (5FU/CBDCA) or cisplatin (CDDP) with intensity-modulated radiation therapy (IMRT) for locally advanced head and neck cancer (LAHNSCC). J Clin Oncol. 2012;30Suppl:Abstr 5537.
36. Pryor DI, Porceddu SV, Burmeister BH, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer. Radiother Oncol. 2009;90(2):172-176.
37. Kao J, Genden EM, Gupta V, et al. Phase 2 trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and hyperfractionated intensity-modulated radiation therapy for locally advanced head and neck cancer. Cancer. 2011;117(2):318-326.
38. Merlano M, Occelli M. Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck. Ther Clin Risk Manag. 2007;3(5):871-876.
39. Seiwert TY, Haraf DJ, Cohen EE, et al. A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). J Clin Oncol. 2011;29Suppl:Abstr 5519.
40. Suntharalingam M, Kwok Y, Goloubeva O, et al. Phase II study evaluating the addition of cetuximab to the concurrent delivery of weekly carboplatin, paclitaxel, and daily radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2012;82(5):1845-1850.
41. Tong CC, Lau KH, Rivera M, et al. Prognostic significance of p16in locoregionally advanced head and neck cancer treated with concurrent 5-fluorouracil, hydroxyurea, cetuximab and intensity-modulated radiation therapy. Oncol Rep. 2012;27(5):1580-1586.
42. Merlano M, Russi E, Benasso M, et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Ann Oncol. 2011;22(3):712-717.
43. Argiris A, Karamouzis MV, Smith R, et al. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Ann Oncol. 2011;22(11):2482-2488.
44. Licitra L, Bergamini C, Olmi P, Soldatenkova V, Ameryckx S, Russo F. Phase I study of concurrent pemetrexed, cetuximab and radiation therapy with or without cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck. Ann Oncol. 2010;21 Suppl 8:1025.
45. Ang KK, Zhang Q, Rosenthal DI, et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). J Clin Oncol. 2011;29Suppl:Abstr 5500.
46. Mesía R, Rueda A, Vera R, et al. Adjuvant therapy with cetuximab for locally advanced squamous cell carcinoma of the oropharynx: results from a randomized, phase II prospective trial. Ann Oncol. 2013;24(2):448-453.
47. Brizel DM, Vokes EE. Induction chemotherapy: to use or not to use? That is the question. Semin Radiat Oncol. 2009;19(1):11-16.
48. Pointreau Y, Atean I, Fayette J, Calais G, Lefebvre JL. Induction chemotherapy in head and neck cancer: a new paradigm. Anticancer Drugs. 2011;22(7):613-620.
49. Specenier PM, Vermorken JB. Neoadjuvant chemotherapy in head and neck cancer: should it be revisited? Cancer Lett. 2007;256(2):166-177.
50. Vokes EE. Induction chemotherapy for head and neck cancer: recent data. Oncologist. 2010;15 Suppl 3:3-7.
51. Argiris A, Heron DE, Smith RP, et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. J Clin Oncol. 2010;28(36):5294-5300.
52. Kies MS, Holsinger FC, Lee JJ, et al. Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol. 2010; 28(1):8-14.
53. Wanebo H, Ghebremichael MS, Burtness B, et al. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72 Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG E2303). J Clin Oncol. 2010;28(15s):Abstr 5513.
54. Adkins D, Ley J, Trinkaus K, et al. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. Cancer. 2013;119(4):766-773.
55. Vermorken JB, Remenar E, van den Weyngaert D, et al. Feasibility of cetuximab plus sequential platinum-based therapy (TPF/CRT) in advanced squamous cell head and neck cancer (SCCHN): a randomized phase II study of the EORTC Head and Neck Cancer Group. Eur Arch Otorhinolaryngol. 2012;269:1311-1410 OP 42 (Abstract).
56. Haddad RI, Tishler RB, Norris C, et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27(27):4448-4453.
57. Jordan W, Wildfang I, Welkoborsky H, et al. TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer. J Clin Oncol. 2010;28(15s):Abstr 5514.
58. Ghi MG, Paccagnella A, Ferrari D, et al. Cetuximab/radiotherapy (CET+RT) versus concomitant chemoradiotherapy (cCHT+RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2 × 2 factorial, phase II-III study (NCT01086826). J Clin Oncol. 2012;30Suppl:Abstr 5513.
59. Lefebvre JL, Pointreau Y, Rolland F, et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized Phase II study. J Clin Oncol. 2013;31:853-859.
60. Keil F, Selzer E, Berghold A, et al. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer. 2013;49(2):352-359.
61. Akmansu M, Buyukberber S, Iren S, et al. Cetuximab concomitant with second-line radiation therapy in patients with locally advanced recurrent squamous cell head and neck cancer. Case Rep Oncol. 2010; 3(3):480-488.
62. Balermpas P, Hambek M, Seitz O, Rödel C, Weiss C. Combined cetuximab and reirradiation for locoregional recurrent and inoperable squamous cell carcinoma of the head and neck. Strahlenther Onkol. 2009;185(12):775-781.
63. Comet B, Kramar A, Faivre-Pierret M, et al. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2012;84(1):203-209.
64. Zwicker F, Roeder F, Thieke C, et al. IMRT reirradiation with concurrent cetuximab immunotherapy in recurrent head and neck cancer. Strahlenther Onkol. 2011;187(1):32-38.
65. Heron DE, Rwigema JC, Gibson MK, Burton SA, Quinn AE, Ferris RL. Concurrent cetuximab with stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: a single institution matched case-control study. Am J Clin Oncol. 2011;34(2):165-172.
66. Kies MS, Harris J, Rotman MZ, et al. Phase II randomized trial of postoperative chemoradiation plus cetuximab for high-risk squamous cell carcinoma of the head and neck (RTOG 0234). Int J Radiat Oncol Biol Phys. 2009;75(3):S14-S15.
67. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol. 2005;23(24):8646-8654.
68. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11):1116-1127.
69. Licitra L, Mesia R, Rivera F, et al. Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study. Ann Oncol. 2011;22(5):1078-1087.
70. Specenier P, Vermorken JB. The role of taxanes and targeted therapies in locally advanced head and neck cancer. Curr Opin Oncol. 2007;19(3):195-201.
71. Hitt R, Irigoyen A, Cortes-Funes H, Grau JJ, García-Sáenz JA, Cruz-Hernandez JJ; Spanish Head and Neck Cancer Cooperative Group (TTCC). Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016-1022.
72. Guigay J, Fayette J, Dillies AF, et al. Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-2003. J Clin Oncol. 2011;29Suppl:Abstr 5567.
73. Clark JI, Greene JB, Lau Clark A, Dalal JS, Hofmeister CC. Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. Med Oncol. 2013;30(1):358.
74. Vermorken JB, Gauler TC, Stoehlmacher-Williams J, et al. Phase II study of pemetrexed plus cisplatin and cetuximab in advanced squamous cell carcinoma of the head and neck. Ann Oncol. 2012;23:ix334-ix347 1022PD (Abstract).
75. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5568-5577.
76. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(24):5578-5587.
77. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol. 2007;25(16):2171-2177.
78. Vermorken JB, Herbst RS, Leon X, Amellal N, Baselga J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer. 2008;112(12):2710-2719.
79. León X, Hitt R, Constenla M, et al. A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy. Clin Oncol (R Coll Radiol). 2005;17(6):418-424.
80. Fury MG, Sherman E, Lisa D, et al. A randomized phase ii study of cetuximab every 2 weeks at either 500 or 750mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J Natl Compr Canc Netw. 2012;10(11):1391-1398.
81. Massa E, Dessì M, Gaspardini G, Saba F, Cherchi V, Mantovani G. Phase II study of vinorelbine/cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck progressing after at least two chemotherapy regimens. Oral Oncol. 2010;46(11):818-821.
82. Knoedler MK, Gauler T, Matzdorff A, et al. Multicenter phase II study of cetuximab plus docetaxel in 84 patients with recurrent or metastatic, platinum-pretreated SCCHN. J Clin Oncol. 2009;27(15s):Abstr 6048.
83. Tinhofer I, Klinghammer K, Weichert W, et al. Expression of amphiregulin and EGFRvIII affect outcome of patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment. Clin Cancer Res. 2011;17(15):5197-5204.
84. Argiris A, Duffy AG, Kummar S, et al. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res. 2011;17(17):5755-5764.
85. Argiris A, Kotsakis AP, Hoang T, et al. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2013;24(1):220-225.
86. StatBite: Radiation therapy plus cetuximab: skin reactions from 71 head and neck cancer patients from 11institutions in Europe. J Natl Cancer Inst. 2010;102(2):75.
87. Azad A. Severe cutaneous toxicity following treatment with radiotherapy and cetuximab: a case report. Cases J. 2009;2(1):25.
88. Billan S, Abdah-Bortnyak R, Kuten A. Severe desquamation with skin necrosis: a distinct pattern of skin toxicity secondary to head and neck irradiation with concomitant cetuximab. Isr Med Assoc J. 2008; 10(3):247.
89. Bölke E, Gerber PA, Lammering G, et al. Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol. 2008;184(2):105-110.
90. Budach W, Bölke E, Homey B. Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med. 2007;357(5):514-515.
91. Chan A, Teoh D, Sanghera P, Hartley A. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer. Radiother Oncol. 2009;93(3):654.
92. Giro C, Berger B, Bölke E, et al. High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol. 2009;90(2):166-171.
93. Koutcher LD, Wolden S, Lee N. Severe radiation dermatitis in patients with locally advanced head and neck cancer treated with concurrent radiation and cetuximab. Am J Clin Oncol. 2009;32(5):472-476.
94. Mydin AR, Armstrong JG. Acneiform rash secondary to cetuximab plus head and neck radiotherapy. Radiother Oncol. 2007;85(1):171.
95. Studer G, Brown M, Salgueiro EB, et al. Grade 3/4 dermatitis in head and neck cancer patients treated with concurrent cetuximab and IMRT. Int J Radiat Oncol Biol Phys. 2011;81(1):110-117.
96. Vano-Galvan S, de las Heras E, Harto A, Jaen P. Severe cutaneous toxicity during concomitant radiotherapy and cetuximab treatment of head and neck cancer. Eur J Dermatol. 2008;18(4):471-472.
97. Waris W, Naik S, Idrees I, et al. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer. Cutan Ocul Toxicol. 2009;28(1):41-44.
98. Langendijk JA, Oosting SF. Grading system and management guidelines for dermatitis induced by head and neck radiotherapy plus cetuximab: clinical validation required. Ann Oncol. 2011;22(10): 2157-2159.
99. Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol. 2008;19(1):142-149.
100. Bernier J, Russi EG, Homey B, et al. Management of radiation dermatitis in patients receiving cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: proposals for a revised grading system and consensus management guidelines. Ann Oncol. 2011;22(10):2191-2200.
101. Grandvuillemin A, Disson-Dautriche A, Miremont-Salamé G, Fourrier-Reglat A, Sgro C; The Reseau des Centres Regionaux de Pharmacovigilance Francais. Cetuximab infusion reactions: French pharmacovigilance database analysis. J Oncol Pharm Pract. Epub November 15, 2012.
102. Hansen NL, Chandiramani DV, Morse MA, Wei D, Hedrick NE, Hansen RA. Incidence and predictors of cetuximab hypersensitivity reactions in a North Carolina academic medical center. J Oncol Pharm Pract. 2011;17(2):125-130.
103. Mesía R, Rivera F, Kawecki A, et al. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol. 2010;21(10):1967-1973.
104. Curran D, Giralt J, Harari PM, et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol. 2007;25(16): 2191-2197.
105. Griffin S, Walker S, Sculpher M, et al. Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Health Technol Assess. 2009;13 Suppl 1:49-54.
106. Brown B, Diamantopoulos A, Bernier J, et al. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. Value Health. 2008;11(5): 791-799.
107. Chan AL, Leung HW, Huang SF. Cost effectiveness of cetuximab concurrent with radiotherapy for patients with locally advanced head and neck cancer in Taiwan: a decision-tree analysis. Clin Drug Investig. 2011;31(10):717-726.
108. Greenhalgh J, Bagust A, Boland A, et al. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technol Assess. 2009;13 Suppl 3:49-54.
109. Hannouf MB, Sehgal C, Cao JQ, Mocanu JD, Winquist E, Zaric GS. Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer. PLoS One. 2012;7(6):e38557.